Trials / Unknown
UnknownNCT04180150
A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B
A Randomized, Double-blinded, Placebo-controlled, Phase IIa Study of TQ-A3334 Combined With Entecavir in the Treatment of Untreated or HBV DNA Negative Subjects With Chronic Hepatitis B
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blinded, placebo-controlled, phase IIa study to evaluate safety and efficacy of TQ-A3334 combined with entecavir in the untreated or HBV DNA negative subjects with Chronic Hepatitis B.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-A3334 | TQ-A3334 is a kind of TLR7 receptor agonist. |
| DRUG | Placebo | Placebo is a treatment which is designed to have no therapeutic value. |
| DRUG | Entecavir Tablet | Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection. |
Timeline
- Start date
- 2019-11-18
- Primary completion
- 2020-09-30
- Completion
- 2021-12-31
- First posted
- 2019-11-27
- Last updated
- 2019-12-16
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04180150. Inclusion in this directory is not an endorsement.